drugset / Trial / NCT04518319

Clinical Intervention on Cognitive Impairment of Schizophrenia With Metabolic Syndrome

NCT04518319

Phase 2 Suspended 120 enrolled Shanghai Mental Health Center
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a single-center, randomized, parallel-control study conducted in schizophrenic inpatients with metabolic syndrome who have been conducted with olanzapine. The purpose of this study is to evaluate the efficacy and safety of omega-3 polyunsaturated fatty acids, Xbox aerobic exercise and transcranial direct current stimulation( tDCS). Following a screening period, subjects who meet the entry criteria will be randomized to treated with omega-3 polyunsaturated fatty acids1.2mg per day, Xbox aerobic exercise 30min per day and tDCS at 2mA, 20 min(5 session/week) for 12 weeks.

Timeline

Start
2020-10-01
Primary completion
2024-11
Completion
2024-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Olanzapine Small molecule
Subject Omega-3 fatty acids Unknown 1200 mg

Indications